Bostwick to Market Metabolon's Prostate Cancer Risk Stratification Test | GenomeWeb

NEW YORK (GenomeWeb News) – Metabolon and Bostwick Laboratories today announced an exclusive marketing agreement covering Metabolon's Prostarix test for stratifying prostate cancer risk.

Under the agreement, Bostwick — a full-service laboratory specializing in uropathology, particularly the diagnosis of urological cancers — will market Prostarix for the initial determination of which men may be candidates for prostate biopsy, as well as the determination of which men who have had prior negative biopsies may need repeat biopsies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: transcriptional and translational study of human cytomegalovirus interactions with host cells, spider web DNA study, and more.

The New York Stem Cell Foundation signs a lease for a new space.

Researchers gear up for an international meeting to discuss the ethics of gene editing.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.